Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Change in Accured Expenses (2022 - 2025)

Historic Change in Accured Expenses for BioXcel Therapeutics (BTAI) over the last 4 years, with Q3 2025 value amounting to -$1.1 million.

  • BioXcel Therapeutics' Change in Accured Expenses rose 3473.81% to -$1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.4 million, marking a year-over-year increase of 6718.49%. This contributed to the annual value of -$4.3 million for FY2024, which is 3442.06% down from last year.
  • Per BioXcel Therapeutics' latest filing, its Change in Accured Expenses stood at -$1.1 million for Q3 2025, which was up 3473.81% from $2.3 million recorded in Q2 2025.
  • BioXcel Therapeutics' 5-year Change in Accured Expenses high stood at $9.2 million for Q4 2022, and its period low was -$12.3 million during Q4 2023.
  • In the last 4 years, BioXcel Therapeutics' Change in Accured Expenses had a median value of -$676000.0 in 2022 and averaged $296333.3.
  • The largest annual percentage gain for BioXcel Therapeutics' Change in Accured Expenses in the last 5 years was 133000.0% (2023), contrasted with its biggest fall of 58846.15% (2023).
  • BioXcel Therapeutics' Change in Accured Expenses (Quarter) stood at $9.2 million in 2022, then plummeted by 233.37% to -$12.3 million in 2023, then soared by 72.96% to -$3.3 million in 2024, then soared by 67.45% to -$1.1 million in 2025.
  • Its Change in Accured Expenses stands at -$1.1 million for Q3 2025, versus $2.3 million for Q2 2025 and -$2.3 million for Q1 2025.